

Review

Open Access

Ultrasound Imaging Versus Morphopathology in Cardiovascular Diseases: The Heart Failure

Giorgio Baroldi*¹, Riccardo Bigi² and Lauro Cortigiani³

Address: ¹Institute of Clinical Physiology, National Research Council, Milan and Pisa, Italy, ²Cardiology, University School of Medicine and Centro Diagnostico Italiano, Milan, Italy and ³Cardiovascular Unit, "Campo di Marte" Hospital, Lucca, Italy

Email: Giorgio Baroldi* - riccardo.bigi@unimi.it; Riccardo Bigi - riccardo.bigi@unimi.it; Lauro Cortigiani - lacortig@tin.it

* Corresponding author

Published: 30 January 2007

Received: 30 November 2006

Cardiovascular Ultrasound 2007, **5**:5 doi:10.1186/1476-7120-5-5

Accepted: 30 January 2007

This article is available from: <http://www.cardiovascularultrasound.com/content/5/1/5>

© 2007 Baroldi et al; licensee BioMed Central Ltd.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/2.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

This review article summarizes the results of histopathological studies to assess heart failure in humans. Different histopathological features underlying the clinical manifestations of heart failure are reviewed. In addition, the present role of echocardiographic techniques in assessing the failing heart is briefly summarized.

Review

Any cardiac disease may end in congestive heart failure (CHF), including coronary heart disease. Since mortality has been reduced in acute coronary syndromes, the latter will be the main condition resulting in CHF. This concept stimulated a systematic, quantitative study in 144 hearts with irreversible insufficiency excised at transplantation compared with 144 hearts without CHF both from patients and normal subjects dead from accident [1]. The aim of this review is to discuss a consensus on CHF which, independently of the underlying disease, is considered: "secondary to absolute or relative ischemia, remodelling of heart shape by enlarged volume, increased mass, cardiac wall thinning, lengthening of cardiomyocytes, continuous infarct expansion, scar formation, apoptosis, hypertrophy, slippage of myocardial cells and increased interstitial fibrosis, and neurohormonal activation" [2].

Our 144 patients with irreversible CHF included 63 with chronic coronary heart disease, 63 with dilated cardiomyopathy and 18 with chronic valvular heart disease. All had a similar clinical pattern. The advantage is that surgically excised hearts are free of any change which may occur in

the terminal, agonic phase and interfere with other autaptic findings.

The main data supporting this review are synthesized in Table 1 and main items in the consensus to be discussed are:

1. Myocardial fibrosis

This variable assumes a central pathogenic meaning since it results (ischemia → continuous infarct expansion → scar) in fibrous, non contracting myocardium ending in progressive insufficiency. In all the three conditions examined, the extent of myocardial fibrosis (Figure 1) was unable to explain myocardial global insufficiency. Even in coronary heart disease group the "fibrous index" (extent percent of myocardial fibrosis found in 16 histologic slides in each heart) showed that the amount of histologically viable myocardium was 83% (98% in dilated cardiomyopathy, 94% in chronic valvulopathy). Furthermore, the increased interstitial fibrosis has ondulate or wavy collagen fibers (Figure 1). This means that collagen fiber hyperplasia is a secondary adaptation to myocardial hypertrophy without any blocking effect on contraction. A last warning is that myocardial fibrosis, especially in large

scar following an infarct necrosis, often is substituted by adipose tissue which can be misinterpreted by clinical imaging concerning myocardial viability [3].

2. Lymphocytic infiltration

In dilated cardiomyopathy the etiopathogenetic hypothesis is that a chronic virus myocarditis resulting in myocardial fibrosis explains this pathologic condition. Both myocardial fibrosis, as already mentioned, and lymphocytic infiltrates, as expression of a virus infection, showed a too low frequency and extent. In particular the number of lymphocytic foci was less than controls in all the insufficient hearts, with a number of elements per focus less than 20. Only in "silent" Chagas patients [apparently healthy subjects serum-positive for this disease who died suddenly and unexpectedly] an extensive lymphocytic myocarditis associated with catecholamine necrosis was observed.

3. Ischemia

A clinical study has shown that ischemic episodes are not part of CHF [4]. On the other hand, in coronary artery disease + CHF group an acute, silent infarct was detected in five of 63 hearts, transmural in two and subendocardial in three with a histological age between 20–30 days. In controls, one Chagas patient had a ten day old anterior infarct and four AIDS subjects, all with normal coronary arteries had a microfocal, four day old infarct in the anterior papillary muscle. If ischemia is the cause of CHF we should have a higher frequency of infarct necrosis.

4. Apoptosis

This genomically programmed cell death, supposed to be triggered by many risk factors, has been recently advocated to explain different cardiac pathologies in which apoptosis has been indirectly "demonstrated" by TUNEL techniques [5]. This necrosis is defined as shrinkage of single cell with fragmentation of its nucleus forming "apoptotic bodies" easy to recognize within or outside the dead cell. The apoptotic cell then disappears without evidence of collagen substitution [6], a finding never observed in our human and experimental material [5]. The claim, that lost of myocardial cells by apoptosis may explain cardiac insufficiency, is contradicted by the heavy weight of insufficient hearts. Lost of myocytes should correspond to normal, if not subnormal heart weight.

5. Thinning cardiac wall/lengthening of myocytes

The weight/size paradox i.e. heavy heart weight with both cardiac wall and myocyte normal thickness is explained by dilatation of heart chambers with lengthening by distension of myocardial cells resulting in normal wall thickness. Such a stretch of myocytes does not occur [1] as shown histologically and ultrastructurally (note in Figure 2). Furthermore, congestive heart failure may occur with

out or with mild chamber enlargement, ventricular dilatation being not an independent prognostic predictor [7].

6. Hypertrophy

By cardiac hypertrophy we mean a tridimensional augmentation in number of myofibrils and other components of myocardial cells to compensate an increase of heart work. The myocyte hypertrophy results in a heavy cardiac weight. When insufficiency begins the weight/size paradox can not be explained by longitudinal division of myocytes never demonstrated or by neogenesis of myocytes [8-10], a concept difficult to be accepted since the hypertrophying stimulus persists and the new elements should hypertrophy.

7. Slippage of myocytes

To explain the paradox, the other well granted hypothesis is that an interpenetration of myocytes may reduce the cardiac wall thickness. First, such never proved interpenetration may explain the latter and dilatation of heart cavities (Figure 2). However, it does not explain normal thickness of myocytes and implies that there is a destruction of a) connecting myobridges between adjacent myocytes b) their interconnection by collagen matrix, and c) a disruption of all interstitial components as vessels (arterial, terminal bed-capillaries, venous and lymphatics) and nerves never seen in this condition.

8. Neurohormonal activation

This assumption has a confirmation in the high frequency of catecholamine necrosis [7] even if the extent of the lesion is very small (Table 1).

The first conclusion is that the pooling of all items of the quoted consensus has no support from morphopathology, but neurohormonal activation which, per se, does not explain congestive failure rather an adrenergic stress prevented by beta-blocking therapy. However, the following two findings not mentioned in this consensus are the following.

9. Colliquative myocytolysis

This non ischemic lesion [7] is typical of congestive heart failure (Figure 3) and, when other conditions (storage diseases) can be excluded, is a reliable histologic hallmark consequent to myocyte insufficiency with increasing lost of myofibrils, intracellular edema in absence of any type of reaction. Its secondary nature is proved by a lack of relationship with clinical indexes of CHF.

10. Endomioelastofibrosis

This change is worthy of mention to avoid any confusion with embologenic endocardial thrombosis. The presence of the latter was 21% in coronary heart disease, 10% in dilated cardiomyopathy and 6% of valvulopathic patients

Table 1: Main findings in 144 hearts with and 144 hearts without congestive heart failure

Source	Total	Age	Heart			Myocardial fibrosis			Intermyocyte lymphocytic infiltration			Catecholamine necrosis			Colliquative myocytolysis					
			cases	yrs	weight g	trans.Ø mm	Ant.LV mm	no	20%	FI	absent	-Mn	+Mn	Foci ×100 mm ²	+	Foci	Myocells	no	[% cells]	
						<	>											<25	25-50	>50
Ischemic heart	63	51 ± 8	565 ± 108	137 ± 14	12 ± 4	-	11	52	17 ± 8	9	38	17	0.2 ± 0.05	59	1 ± 1	10 ± 14	1	14	39	9
Dilated cardiom.	63	42 ± 12	639 ± 155	148 ± 15	15 ± 4	8	54	1	2 ± 3	8	42	18	0.4 ± 0.18	53	2 ± 6	12 ± 26	3	28	28	4
Valvulopathy	18	46 ± 8	827 ± 179	147 ± 15	16 ± 4	-	14	4	4 ± 4	3	12	7	0.3 ± 0.09	14	1 ± 2	5 ± 6	1	2	14	1
Total+CHF*	144	46 ± 9	677 ± 147	144 ± 15	14 ± 4	8	79	57	8 ± 5	20	92	42	0.3 ± 0.09	126	1 ± 3	9 ± 15	5	44	81	14
Chagas	34	49 ± 13	464 ± 110	114 ± 18	15 ± 3	9	18	7	7 ± 8	-	34	31	13 ± 2	34	3 ± 6	30 ± 51	28	6	-	-
AIDS	38	31 ± 10	368 ± 67	91 ± 21	13 ± 3	34	4	-	0.04 ± 1	14	16	9	1.5 ± 0.7	25	4 ± 11	13 ± 27	33	3	2	-
Brain hemorrhage	27	58 ± 12	434 ± 91	107 ± 15	18 ± 7	12	15	-	0.4 ± 6	15	7	-	2 ± 1.8	24	26 ± 34	67 ± 104	26	-	1	-
Head trauma normal	45	42 ± 17	364 ± 47	104 ± 15	12 ± 6	45	-	-	-	29	11	-	5 ± 3	9***	10 ± 18	23 ± 31	45	-	-	-
Total without CHF	144	45 ± 17	408 ± 79	104 ± 17	15 ± 5	100	37	7	2 ± 5	58	68	40	5 ± 1.9	92	11 ± 17	33 ± 53	132	9	3	-

* Heart excised at transplantation; ** Mn, myocyte necrosis non [-] or [+] associated with lymphocytes; *** Survival < 1 hour. No necrosis in instantaneous death; Ant LV, thickness anterior left ventricle; trans. Ø, transvers diameter




Figure 1

Stretched, i.e. elongation of sarcomeres and nuclei in viable myocardial cells in an old aneurysm of the left ventricular wall with dense fibrosis [A]. Dense and compact fibrosis as end result of a repair process of an infarct. The collagen fibers are straight and closed together [B]. In contrast in hearts with congestive heart failure the myocardial fibrosis is very mild [C, D] showing a corkscrew aspect of the collagen fibers [E]. This means an adaptation of the collagenogenesis to the contraction cycle without any capability to reduce or stop the latter. Furthermore, the fibrous tissue may metaplasize in adipose tissue which substitutes large fibrous area [F, G]. A fact to have in mind when quantifying the size of a scar or measuring by nuclear method the myocardial viability.

with CHF. Most of these endocardial thrombi were organized. Myoelastofibrosis was demonstrated in 98% of congestive hearts being present also in controls (Table 2). It starts as smooth muscle cell nodular proliferation below the normal endothelial cells of the endocardium (Figure 4), followed by elastic fiber hyperplasia and ending in fibrous thickening without evidence of overimposed thrombosis or repair process.

Target of Ultrasound Diagnosis: Present and Future

Though various imaging techniques have been introduced for assessing left ventricular function, echocardiography still represents the main choice in the clinical arena due to its unique combination of safety, feasibility, and reliability (Table 3). Both diastolic and systolic function of the heart can be easily explored by echocardiography.




Figure 2

Weight/size paradox in congestive heart failure. The slippage of myocardial cell to explain a normal wall and myocellular size despite a heavy cardiac weight [A], does not consider the myofibrillar bridging between myocells and fibrillar collagen connections. Slippage of myocells, capable to reduce for instance a 3 cm cardiac wall in 1.5 one, should imply an extensive destruction of all interstitial structures [vessels, including lymphatics, and nerves] and consequent widespread tissue damage never seen in this condition. Even a neogenesis of the myocardial cell was never observed. Only once in an endomyocardial biopsy at a previous site of sampling in a transplanted heart, we had the opportunity to see new myocells forming a focus of small elements assuming the aspect of atrio-ventricular node [B, C]. Just to emphasize that a neogenesis when exists can be seen, apparently without integration in the functioning myocardium.

I. Diastolic function

Doppler echocardiography traditionally allows diastolic abnormalities affecting overall cardiac function to be easily detected on routine examination. Inversion of the E/A ratio and prolongation of deceleration time on the transmitral flow pattern represent the first abnormalities which are encountered in the minor stage of diastolic dysfunction. A restrictive filling pattern, reflecting an increased pulmonary capillary pressure, is observed in case of more severe dysfunction and is associated to adverse outcome [11]. More recently, Tissue Doppler Imaging (TDI) has provided robust, relatively unambiguous, well validated tool that is more reliable than the use of pulmonary vein

Doppler, flow propagation velocity or load altering techniques [12].

The clinical role of echocardiography for evaluating diastolic function is quite different depending on whether global left ventricular (LV) systolic function is preserved or not. In patients with preserved systolic function, measurement of transmitral flow in combination with mitral annular tissue Doppler velocities provide the most efficient means of assessing LV diastolic function and filling pressures. However, in case of global systolic dysfunction and accompanying diastolic dysfunction, the principal aim of Doppler echocardiography is to estimate filling pressure, which has known therapeutic and prognostic




Figure 3

Colliquative myocytolysis. Progressive disappearance of myofibrils [A], with intramyocardial edema [B] resulting in empty sarcolemmal tube seen in longitudinal [C] and transverse section [D]. Note the absence of any type of reaction. E, ultrastructural view of an edematous myocyte filled by mitochondria and few contracted myofibrils in contrast with a normal contracted myocyte [F] of the same case with congestive heart failure.

implications [13]. In these patients, diastolic Doppler parameters are principally used to determine LV filling pressures [13]. Finally, when the regional assessment of the diastolic function is the target, TDI presently represents the best echocardiographic approach.

2. Systolic function

Initially described in studies including contrast or radio-nuclide ventriculography, global and regional left ventricular function are optimally assessed with echocardiographic technique in both resting and stress condition. With the ultrasound beam directed perpendic-

ularly to the myocardium, wall motion and thickening can easily be detected on the imaging plane. Several imaging windows, including parasternal, apical, and subcostal views, are used to visualize all ventricular walls. More recently, three dimensional (3D) echocardiographic images are generated by integration of information from multiple 2D imaging planes. In addition, the introduction of harmonic imaging and the use of echocardiographic contrast media for improved endocardial border definition have significantly improved image quality, thereby enhancing the accuracy of assessment of left ventricular function particularly in patients with poor acoustic win-

Table 2: Frequency of endocardial myoelastofibrosis in different conditions

Source	Endocardial myofibroelastosis						
	Cases	Absent	Nodular myohyperplasia	Myofibro elastosis	LV	RV	IV
Congestive heart failure*	144	3	15	126	129	29	125
Sudden/unexpected coronary death	25	13	2	10	6	6	9
Sudden/unexpected death silent Chagas	34	15	1	18	17	6	10
Transplanted hearts	46	29	6	11	11	5	6
Intracranial brain hemorrhage	27	10	3	14	13	4	9
AIDS	38	16	7	15	11	5	11
Cocaine abusers**	26	19	5	2	2	-	-
Carbon monoxide intoxication**	26	26	-	-	-	-	-
Head trauma**	45	45	-	-	-	-	-
Electrocution**	21	21	-	-	-	-	-

* Hearts excised at transplantation ** Only anterior left ventricle available for study; LV, left ventricle; RV right ventricle; IV, interventricular septum

dows. Estimation of the LVEF by 2D echocardiography can be done either qualitatively by visual inspection of global and regional function or quantitatively, using geometric assumptions regarding the shape of the LV cavity.

Global and regional LV systolic function can both be qualitatively and quantitatively assessed with echocardiography.

Global function is qualitatively described as normal, depressed, or hyperdynamic. Although a comprehensive quantitative assessment of LV end-systolic and end-diastolic data would be ideal, such an approach is currently impractical for routine evaluation. Several quantitative approaches have been described, with Simpson's rule (disk-area method) being the most accurate for LV volume measurement and for computation of derived values such as LV ejection fraction [14]. Perhaps this assessment may be obtained in the future with further development of 3D techniques and improved automated edge-detection algorithms.

The regional assessment of LV systolic function is assessed by dividing the entire left ventricle into segments. The most popular models recommend the use of 16 or 17 segments [15,16]. A score is then assigned to each segment: (1 = normal, 2 = hypokinesis, 3 = akinesis, 4 = dyskinesis) and a semiquantitative wall motion score index is derived as the ratio between the sum of scores assigned to each segment and the number of visualized segments.

Future developments for the assessment of ventricular function with echocardiography include the use of 3D technique and myocardial strain imaging.

3D echocardiography offers the theoretical advantage to provide incremental benefit over 2D techniques in terms of accuracy and reproducibility and appears to produce estimation of LV ejection fraction similar to radionuclide

ventriculography and cardiovascular magnetic resonance [17-21].

The term "strain" refers to an object's fractional or percentage change from its original dimension [22,23], thus reflecting the deformation of a structure. When applied to the myocardium, strain directly describes the contraction/relaxation pattern and can be calculated in several dimensions [23]. Strain rate represents the rate of this deformation [22]. Strain rate imaging involves mathematical subtraction of the whole heart or translational motion from regional thickening velocity using a transmural data set from color-coded tissue Doppler echo [24,25]. This quantification of the spatial distribution of intramural velocities across the myocardium has improved the ability of tissue Doppler echo to reflect directional and incremental alterations in regional and global left ventricular contractility in patients with cardiovascular disease [24-27]. Though very promising for assessing several aspect of myocardial function, strain and strain rate imaging presently are of limited applicability in clinical practice due to several limitations [23], such as complex methodology, technical challenges of image acquisition, susceptibility to artefact and lack of standardization.

Conclusion

The cause of CHF is still unknown, with the impression, based on morphopathologic data, that its pathogenesis consists in a primary metabolic error of myocytes which lost their ability to relax in the contraction cycle. At ultrastructure these elements are in contraction and this finding may indicate the inability to remove Ca⁺² from troponin-tropomyosine complex. The metabolic error could stimulate an abortive hypertrophy with elongation of myocytes by new sarcomeres with normal length without tridimensional myofibrillar iperplasia [1,4].




Figure 4
 Endomyoelastofibrosis of the endocardium. Thickening of the endocardium is considered consequent to intracavitary thrombi organization. The latter is a relatively rare event. The majority of endocardial thickening is due to the formation of smooth muscle cell bundles [A] with hyperelastosis [B] ending in fibrous replacement [C]. A process similar to that shown in the early pathogenesis of an atherosclerotic plaque, to keep in mind in relation to antithrombotic therapy.

Table 3: Noninvasive technique for assessing left ventricular function.

	<i>Echocardiography</i>	<i>Nuclear scan</i>	<i>Cardiac CT</i>	<i>Cardiac MRI</i>
Radiation exposure	-	+	+	-
Patient dependence	+	-	-	-
Operator dependence	+	-	-	-
Imaging time	+	++	+	+++
Installation costs	+	++	+++	++++
Operation costs	+	++	+++	++++
Spatial resolution	+++	+	+++	+++
Temporal resolution	+++	+	++	±

CT: computed tomography

MRI: magnetic resonance imaging

Reproduced from Picano E.: *Stress Echocardiography*. 4th edition. Verlag: Springer; 2003

Competing interests

The author(s) declare that they have no competing interests.

Authors' contributions

GB conceived and drafted the manuscript. RG and LC critically revised and helped to draft the manuscript. All authors read and approved the final manuscript.

References

- Baroldi G, Silver MD, De Maria R: **Pathology and pathogenesis of congestive heart failure. A quantitative morphologic study of 144 hearts excised at transplantation.** *Pathogenesis* 1998, **1**:107.
- Cohn JN, Ferrari R, Sharpe N: **Cardiac remodeling. Concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling.** *J Am Coll Cardiol* 2000, **35**:569-82.
- Baroldi G, Silver MD, De Maria R, Parodi O, Pellegrini A: **Lipomatous metaplasia in left ventricular scar.** *Can J Cardiol* 1997, **13**:65-71.
- Pool Wilson PA: **Relation of pathophysiologic mechanisms to outcome in heart failure.** *J Am Coll Cardiol* 1993, **22**:22A-29A.
- Baroldi G, Silver MD: **The etiopathogenesis of coronary heart disease: a heretical theory based on morphology.** *Medical Intelligence Unit* 2nd edition. 2004 [<http://www.eurekah.com/pubnote/>]. Eurekah-Com, Landes Bioscience, Georgetown, Texas, USA
- Majno G, Joris I: **Apoptosis, oncosis and necrosis. An overview of cell death.** *Am J Path* 1995, **146**:3-15.
- Gavazzi A, De Maria R, Renosto G, Moro A, Borgia M, Caroli A, Castellani G, Ciaccheri M, Pavan D, De Vita C: **The spectrum of left ventricular size in dilated cardiomyopathy: clinical correlates and prognostic implication. SPIC (Italian Multicenter Cardiomyopathy Study) Group.** *Am Heart J* 1993, **125**:410-422.
- Beltrami CA, Di Loreto C, Finato N, Rocco M, Artico D, Cigola E, Gambert SR, Olivetti G, Kajstura J, Anversa P: **Proliferating cell nuclear antigen [PCNA], DNA synthesis and mitosis in myocytes following cardiac transplantation in man.** *J Mol Cell Cardiol* 1997, **29**:2789-2802.
- Beltrami AP, Urbanek K, Kajstura J, Yan SM, Finato N, Bussani R, Nadal-Ginard B, Silvestri F, Leri A, Beltrami CA, Anversa P: **Evidence that human cardiac myocytes divide after myocardial infarction.** *N Engl J Med* 2001, **344**:1750-1757.
- Baroldi G, Bigi R, Cortigiani L: **Ultrasound imaging versus morphopathology. Myocardial cell damage.** *Cardiovascular Ultrasound* 2005, **3**:32.
- Kuecherer HF, Duffman K, Schaefer E, Kuebler W: **Doppler echocardiographic assessment of left ventricular filling dynamics in patients with coronary artery disease and normal systolic function.** *Eur Heart J* 1988, **9**:649-656.
- Ommen SR, Nishimura RA, Appleton CP, Miller FA, Oh JK, Redfield MM, Tajik AJ: **Clinical utility of Doppler echocardiography and tissue Doppler imaging in the estimation of left ventricular filling pressures: a comparative simultaneous Doppler catheterization study.** *Circulation* 2000, **102**:1788-94.
- Mottram M, Marwick TH: **Assessment of diastolic function: what the general cardiologists needs to know.** *Heart* 2005, **91**:681-695.
- Folland ED, Parisi AF, Moynihan PF, Jones DR, Feldman CL, Tow DE: **Assessment of left ventricular ejection fraction and volumes by real-time, two-dimensional echocardiography. A comparison of cineangiographic and radionuclide techniques.** *Circulation* 1979, **60**:760-766.
- Schiller NB, Shah PM, Crawford M, DeMaria A, Devereux R, Feigenbaum H, Gutgesell H, Reichek N, Sahn D, Schnittger I: **Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms.** *J Am Soc Echocardiogr* 1989, **2**:358-367.
- Cerqueira MD, Weissman NJ, Dilsizian V, Jacobs AK, Kaul S, Laskey WK, Pennell DJ, Rumberger JA, Ryan T, Verani MS, American Heart Association Writing Group on Myocardial Segmentation and Registration for Cardiac Imaging: **Standardized myocardial segmentation and nomenclature for tomographic imaging of the heart: a statement for healthcare professionals from the Cardiac Imaging Committee of the Council on Clinical Cardiology of the American Heart Association.** *Circulation* 2002, **105**:539-542.
- Gopal AS, Shen Z, Sapin PM, Keller AM, Schnellbaecher MJ, Leibowitz DW, Akinboboye OO, Rodney RA, Blood DK, King DL: **Assessment of cardiac function by three-dimensional echocardiography compared with conventional noninvasive methods.** *Circulation* 1995, **92**:842-853.
- Nosir YF, Fioretti PM, Vletter WB, Boersma E, Salustri A, Postma JT, Reijs AE, Ten Cate FJ, Roelandt JR: **Accurate measurement of left ventricular ejection fraction by three-dimensional echocardiography. A comparison with radionuclide angiography.** *Circulation* 1996, **94**:460-466.
- Danias PG, Chuang ML, Parker RA, Beaudin RA, Mooney MG, Manning WJ, Douglas PS, Hibberd MG: **Relations between the number of image planes and the accuracy of three-dimensional echocardiography for measuring left ventricular volumes and ejection fraction.** *Am J Cardiol* 1998, **82**:1431-1434.
- Nosir YF, Lequin MH, Kasprzak JD, van Domburg RT, Vletter WB, Yao J, Stoker J, Ten Cate FJ, Roelandt JR: **Measurements of day-to-day variables of left ventricular volumes and ejection fraction by three-dimensional echocardiography and comparison with magnetic resonance imaging.** *Am J Cardiol* 1998, **82**:209-214.
- Kuhl HP, Schreckenber M, Rulands D, Katoh M, Schafer W, Schummers G, Bucker A, Hanrath P, Franke A: **High-resolution transthoracic real-time three-dimensional echocardiography: quantitation of cardiac volumes and function using semi-automatic border detection and comparison with cardiac magnetic resonance imaging.** *J Am Coll Cardiol* 2004, **43**:2083-2090.
- Abraham TP, Nishimura RA: **Myocardial strain: can we finally measure contractility?** *J Am Coll Cardiol* 2001, **37**:731.
- Marwick TH: **Measurement of strain and strain rate by echocardiography: ready for prime time?** *J Am Coll Cardiol* 2006, **47**:1313-1327.
- Sutherland GR, Di Salvo G, Claus P, D'hooge J, Bijnens B: **Strain and strain rate imaging: a new clinical approach to quantifying regional myocardial function.** *J Am Soc Echocardiogr* 2004, **17**:788-802.
- Uematsu M, Miyatake K, Tanaka N, Matsuda H, Sano A, Yamazaki N, Hirami M, Yamagishi M: **Myocardial velocity gradient as a new indicator of regional left ventricular contraction: detection by a two-dimensional tissue Doppler imaging technique.** *J Am Coll Cardiol* 1995, **26**:217-223.
- Uematsu M, Nakatani S, Yamagishi M, Matsuda H, Miyatake K: **Usefulness of myocardial velocity gradient derived from two-dimensional tissue Doppler imaging as an indicator of regional myocardial contraction independent of translational motion assessed in atrial septal defect.** *Am J Cardiol* 1997, **79**:237-241.
- Edvardsen T, Skulstad H, Aakhus S, Urheim S, Ihlen H: **Regional myocardial systolic function during acute myocardial ischemia assessed by strain Doppler echocardiography.** *J Am Coll Cardiol* 2001, **37**:726-773.

Publish with **BioMed Central** and every scientist can read your work free of charge

"BioMed Central will be the most significant development for disseminating the results of biomedical research in our lifetime."

Sir Paul Nurse, Cancer Research UK

Your research papers will be:

- available free of charge to the entire biomedical community
- peer reviewed and published immediately upon acceptance
- cited in PubMed and archived on PubMed Central
- yours — you keep the copyright

Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp

